Скачать или смотреть Adding chemotherapy to immunotherapy in metastatic CRC

Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, presents data from the phase Ib KEYNOTE-651 trial (NCT03374254), which assessed pembrolizumab with modified FOLFOX7 or FOLFIRI in patients with metastatic colorectal cancer (mCRC). In two out of five cohorts, patients with microsatellite stable CRC were given first- or second-line pembrolizumab with modified FOLFOX7 or FOLFIRI and the progression-free survival (PFS) was found to be comparable to that of patients not receiving pembrolizumab. Dr Kim additionally discusses the efficacy of certain biomarkers such as PD-L1 levels and the mutational status of KRAS in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.